1. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2001;163(6):1304-9.
2. Barnes PJ. Chronic obstructive pulmonary disease. The New England journal of medicine. 2000;343(4):269-80.
3. Kim WD, Chi HS, Choe KH, Kim WS, Hogg JC, Sin DD. The Role of Granzyme B Containing Cells in the Progression of Chronic Obstructive Pulmonary Disease. Tuberculosis and respiratory diseases. 2020;83(Supple 1):S25-s33.
4. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. American journal of respiratory and critical care medicine. 1996;153(5):1530-5.
5. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995-2004.
6. Chen CZ, Ou CY, Wang WL, Lee CH, Lin CC, Chang HY, et al. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity. Copd. 2012;9(3):276-80.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2020 [accessed 2021 April 21]. Available from: http://www.goldcopd.org/.
8. Celli BR, Anderson JA, Cowans NJ, Crim C, Hartley BF, Martinez FJ, et al. Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. American journal of respiratory and critical care medicine. 2021;203(6):689-98.
9. Lee HW, Park J, Jo J, Jang EJ, Lee CH. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. PLoS medicine. 2019;16(11):e1002958.
10. Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. The New England journal of medicine. 2015;373(2):111-22.
11. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. American journal of respiratory and critical care medicine. 2006;173(9):985-90.
12. Tantucci C, Modina D. Lung function decline in COPD. International journal of chronic obstructive pulmonary disease. 2012;7:95-9.
13. Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2016;194(2):178-84.
14. Whittaker HR, Pimenta JM, Jarvis D, Kiddle SJ, Quint JK. Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease. International journal of chronic obstructive pulmonary disease. 2020;15:3079-91.
15. Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli B, et al. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respiratory medicine. 2013;107(12):1904-11.
16. Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, et al. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2017;195(3):324-30.
17. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-52.
18. Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks JW, et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020;75(9):744-53.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453-7.
20. Lee JY, Chon GR, Rhee CK, Kim DK, Yoon HK, Lee JH, et al. Characteristics of Patients with Chronic Obstructive Pulmonary Disease at the First Visit to a Pulmonary Medical Center in Korea: The KOrea COpd Subgroup Study Team Cohort. Journal of Korean medical science. 2016;31(4):553-60.
21. Fletcher C, Peto R. The natural history of chronic airflow obstruction. British medical journal. 1977;1(6077):1645-8.
22. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. The New England journal of medicine. 2011;365(13):1184-92.
23. Marott JL, Ingebrigtsen TS, Çolak Y, Vestbo J, Lange P. Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. American journal of respiratory and critical care medicine. 2020;202(2):210-8.
24. Raimondi GA. FEV(1) Decline in Patients with Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2017;195(12):1676-7.
25. Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, et al. High eosinophil counts predict decline in FEV(1): results from the CanCOLD study. The European respiratory journal. 2021;57(5).
26. MacDonald MI, Osadnik CR, Bulfin L, Hamza K, Leong P, Wong A, et al. Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD. Chest. 2019;156(1):92-100.
27. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. The European respiratory journal. 2014;44(6):1697-700.
28. Prudente R, Ferrari R, Mesquita CB, Machado LHS, Franco EAT, Godoy I, et al. Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients. International journal of chronic obstructive pulmonary disease. 2021;16:979-85.
29. Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH, et al. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respiratory research. 2018;19(1):134.
30. Singh D. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. Tuberculosis and respiratory diseases. 2020;83(3):185-94.
31. Stănescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267-71.
32. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. The European respiratory journal. 2001;17(6):1112-9.
33. Talaminos Barroso A, Márquez Martín E, Roa Romero LM, Ortega Ruiz F. Factors Affecting Lung Function: A Review of the Literature. Archivos de bronconeumologia. 2018;54(6):327-32.
34. Watson L, Vonk JM, Löfdahl CG, Pride NB, Pauwels RA, Laitinen LA, et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respiratory medicine. 2006;100(4):746-53.
35. Triebner K, Matulonga B, Johannessen A, Suske S, Benediktsdóttir B, Demoly P, et al. Menopause Is Associated with Accelerated Lung Function Decline. American journal of respiratory and critical care medicine. 2017;195(8):1058-65.
36. Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten Hacken NH, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax. 2006;61(2):105-10.
37. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet (London, England). 2017;389(10082):1919-29.
38. Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ (Clinical research ed). 2018;363:k4388.
39. Calzetta L, Matera MG, Rogliani P, Cazzola MJERoCP. The role of triple therapy in the management of COPD. 2020;13(8):865-74.
40. Voorham J, Kerkhof M, Georges G, Vezzoli S, Papi A, Vogelmeier C, et al. Comparative Real-World Effectiveness of Triple Therapy Versus Dual Bronchodilation on Lung Function Decline in Frequently Exacerbating Patients with COPD. B45 COPD: TREATMENT: American Thoracic Society; 2019. p. A3314-A.